|
|
Article: Thallion Announces Positive Safety and Efficacy Data From ECO-4601 Phase I/II Trial
- Article from:
- CCNMatthews Newswire
- Article date:
- November 15, 2007
CopyrightCopyright 2007 CCNMatthews Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
MONTREAL, QUEBEC--(Marketwire - Nov. 15, 2007) - Thallion
Pharmaceuticals Inc. (TSX:TLN) today presented positive safety and
efficacy data from the completed Phase I/II trial of ECO-4601 for
the treatment of advanced cancer patients. These results support and
confirm preliminary results from the dose escalation portion of the
study disclosed earlier this year at the annual ASCO meeting. ECO-
4601 was safe and well-tolerated up to the maximum dose tested of
480mg/m2/day. Adverse events potentially related to ECO-4601 were
nonspecific and common in this type of patient population.
Furthermore, in seven refractory cancer patients who had completed
six cycles of treatment, six patients achieved ...